373 related articles for article (PubMed ID: 32754615)
21. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Nouri M; Ratther E; Stylianou N; Nelson CC; Hollier BG; Williams ED
Front Oncol; 2014; 4():370. PubMed ID: 25566507
[TBL] [Abstract][Full Text] [Related]
22. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R; Paranjape AN; Maity S; Aparicio A; Mani SA
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):229-238. PubMed ID: 29981816
[TBL] [Abstract][Full Text] [Related]
23. Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States.
Bornes L; Belthier G; van Rheenen J
J Clin Med; 2021 May; 10(11):. PubMed ID: 34072345
[TBL] [Abstract][Full Text] [Related]
24. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
26. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
[TBL] [Abstract][Full Text] [Related]
27. Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy.
Baram T; Rubinstein-Achiasaf L; Ben-Yaakov H; Ben-Baruch A
Front Oncol; 2020; 10():614468. PubMed ID: 33585241
[TBL] [Abstract][Full Text] [Related]
28. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Cancer Drug Resist; 2019; 2(2):297-312. PubMed ID: 35582717
[TBL] [Abstract][Full Text] [Related]
29. Unpacking the Complexity of Epithelial Plasticity: From Master Regulator Transcription Factors to Non-Coding RNAs.
Waryah C; Alves E; Mazzieri R; Dolcetti R; Thompson EW; Redfern A; Blancafort P
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370762
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
31. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.
Han M; Li F; Zhang Y; Dai P; He J; Li Y; Zhu Y; Zheng J; Huang H; Bai F; Gao D
Cancer Cell; 2022 Nov; 40(11):1306-1323.e8. PubMed ID: 36332622
[TBL] [Abstract][Full Text] [Related]
32. A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer.
Ware KE; Thomas BC; Olawuni PD; Sheth MU; Hawkey N; Yeshwanth M; Miller BC; Vietor KJ; Jolly MK; Kim SY; Armstrong AJ; Somarelli JA
Front Mol Biosci; 2023; 10():1104505. PubMed ID: 37228586
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
Liu S; Alabi BR; Yin Q; Stoyanova T
Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
[TBL] [Abstract][Full Text] [Related]
34. Cancer plasticity: Investigating the causes for this agility.
Saha S; Pradhan N; B N; Mahadevappa R; Minocha S; Kumar S
Semin Cancer Biol; 2023 Jan; 88():138-156. PubMed ID: 36584960
[TBL] [Abstract][Full Text] [Related]
35. Cellular Plasticity in Cancer.
Yuan S; Norgard RJ; Stanger BZ
Cancer Discov; 2019 Jul; 9(7):837-851. PubMed ID: 30992279
[TBL] [Abstract][Full Text] [Related]
36. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract][Full Text] [Related]
37. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
38. Cell Plasticity and Prostate Cancer: The Role of Epithelial-Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance.
Papanikolaou S; Vourda A; Syggelos S; Gyftopoulos K
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199763
[TBL] [Abstract][Full Text] [Related]
39. Polycomb-mediated silencing in neuroendocrine prostate cancer.
Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
[TBL] [Abstract][Full Text] [Related]
40. Cellular plasticity and drug resistance in sarcoma.
Lin Z; Fan Z; Zhang X; Wan J; Liu T
Life Sci; 2020 Dec; 263():118589. PubMed ID: 33069737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
